Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | HTR7 | P34969 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4932349 | 0.99 | CACNA1G (0.53) | CACNA1GDRD2DRD3HTR7KDM4E | |
| SCHEMBL4684360 | 0.93 | HTR7 (0.53) | CACNA1GDRD2DRD3HTR7KDM4E | |
| SCHEMBL4689618 | 0.88 | SIGMAR1 (0.53) | DRD2DRD3HTR7ALDH1A1TDP1 | |
| SCHEMBL4687765 | 0.87 | SIGMAR1 (0.52) | DRD2DRD3HTR7ALDH1A1TDP1 | |
| SCHEMBL4687764 | 0.87 | DRD2 (0.51) | DRD2DRD3HTR7SIGMAR1DRD5 | |
| SCHEMBL4684342 | 0.86 | SIGMAR1 (0.54) | DRD2DRD3HTR7ALDH1A1TDP1 | |
| SCHEMBL4687911 | 0.85 | DRD2 (0.50) | CACNA1GDRD2DRD3HTR7KDM4E | |
| SCHEMBL4689638 | 0.85 | HTR7 (0.51) | DRD2DRD3HTR7SIGMAR1DRD5 | |
| SCHEMBL4687021 | 0.85 | DRD2 (0.63) | DRD2DRD3HTR7SIGMAR1DRD5 | |
| SCHEMBL4688657 | 0.84 | HTR7 (0.55) | DRD2DRD3HTR7SIGMAR1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | disclosed |
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | disclosed |
| EP-1828125-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | CACNA1G 2562/4885DRD2 8/4885DRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.